C12N 2740/13071
Demonstrated in vivo effect
C12N2740/13071 (Demonstrated in vivo effect) appears on 9 US grants and 17 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 17
- Assignees
- 9
- Inventors
- 19
- Latest grant
- 19 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 1 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 2 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 1 |
| 2016 | 0 | 0 |
| 2017 | 1 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 1 |
| 2021 | 0 | 3 |
| 2022 | 1 | 1 |
| 2023 | 2 | 0 |
| 2024 | 1 | 3 |
| 2025 | 2 | 2 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for inducing immune responses19 Aug 2025US 12,390,524 B2Arcturus Therapeutics, Inc.
- Coronavirus vaccine compositions and methods11 Feb 2025US 12,220,455 B2Arcturus Therapeutics, Inc.
- Feline leukemia virus vaccine3 Sep 2024US 12,076,392 B2Intervet Inc.
- Compositions and methods for inducing immune responses19 Sep 2023US 11,759,515 B2Arcturus Therapeutics, Inc.
- Coronavirus vaccine compositions and methods5 Sep 2023US 11,744,887 B2Arcturus Therapeutics, Inc.
- Compositions and methods for inducing immune responses12 Mar 2026US 2026/0069677 A1Arcturus Therapeutics, Inc.
- Immunotherapeutic compositions for treatment of glioblastoma multiforme18 Dec 2025US 2025/0381266 A1Variation Biotechnologies Inc.
- Coronavirus vaccine compositions and methods22 May 2025US 2025/0161434 A1Arcturus Therapeutics, Inc.
- Feline leukemia virus vaccine5 Dec 2024US 2024/0398934 A1Intervet Inc.
- Coronavirus vaccine compositions and methods11 Apr 2024US 2024/0115691 A1Arcturus Therapeutics, Inc.
Most cited
By later US patents
- Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect12US 7,005,126 B1Human Gene Therapy Research Institute · 2006
- Coronavirus vaccine compositions and methods4US 11,744,887 B2Arcturus Therapeutics, Inc. · 2023
- Coronavirus vaccine compositions and methods2US 12,220,455 B2Arcturus Therapeutics, Inc. · 2025
- Feline leukemia virus vaccine1US 11,311,616 B2Intervet Inc. · 2022
- Compositions and methods for inducing immune responses1US 11,759,515 B2Arcturus Therapeutics, Inc. · 2023